Effect of primary anthracycline-based chemotherapy on disseminated tumor cells in locally advanced breast cancer

被引:0
|
作者
Jäger, C [1 ]
Kafka, A [1 ]
Bossert, S [1 ]
Grundmann, R [1 ]
Windisch, J [1 ]
Kreienberg, R [1 ]
Heilmann, V [1 ]
机构
[1] Univ Ulm, Dept Obstet & Gynecol, D-89075 Ulm, Germany
关键词
breast cancer; disseminated tumor cells; anthracycline-based; chemotherapy;
D O I
暂无
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background: The leading cause of death from epithelial cancer is metastatic tumor relapse due to early dissemination of tumor cells. In this study we investigated the elimination rate of disseminated tumor cells in bone marrow and the clinical response under primary chemotherapy in locally advanced breast cancer. Patients and Methods: Thirty patients underwent primary anthracycline-containing chemotherapy for breast cancer. For immunocytochemical tumor cell detection in bone marrow, the monoclonal antibody 5D3 was used. Results: At time of diagnosis, 10/30 (33%) patients had cytokeratin-positive tumor cells in bone marrow. After primary and chemotherapy, 8/30 (27%) patients still tested positive. Clinical complete response (cCR) was observed in 5/30 (17%) patients partial response (cPR) in 12/30 (40%) patients, resulting in an overall rate of clinical response to primary chemotherapy in 57%. Conclusion: Primary chemotherapy in breast cancer is effective regarding the reduction of tumor size but seems incapable of reducing the burden of disseminated tumor cells in bone marrow.
引用
收藏
页码:3209 / 3214
页数:6
相关论文
共 50 条
  • [31] The incidence of symptomatic thromboembolism in patients receiving adjuvant anthracycline-based chemotherapy for early stage breast cancer
    Nolan, Luke
    Darby, Angela
    Boleti, Katia
    Simmonds, Peter
    BREAST, 2011, 20 (02) : 151 - 154
  • [32] Topoisomerase IIα expression rather than gene amplification predicts responsiveness of adjuvant anthracycline-based chemotherapy in women with primary breast cancer
    Schindlbeck, Christian
    Mayr, D.
    Olivier, C.
    Rack, B.
    Engelstaedter, V.
    Jueckstock, J.
    Jenderek, C.
    Andergassen, U.
    Jeschke, U.
    Friese, K.
    JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2010, 136 (07) : 1029 - 1037
  • [33] Topoisomerase IIα expression rather than gene amplification predicts responsiveness of adjuvant anthracycline-based chemotherapy in women with primary breast cancer
    Christian Schindlbeck
    D. Mayr
    C. Olivier
    B. Rack
    V. Engelstaedter
    J. Jueckstock
    C. Jenderek
    U. Andergassen
    U. Jeschke
    K. Friese
    Journal of Cancer Research and Clinical Oncology, 2010, 136 : 1029 - 1037
  • [34] Simultaneous detection of circulating and disseminated tumor cells in primary breast cancer patients following neoadjuvant chemotherapy
    Vincent P. Walter
    Florin-Andrei Taran
    Markus Wallwiener
    Markus Hahn
    Sara Y. Brucker
    Andreas D. Hartkopf
    Archives of Gynecology and Obstetrics, 2018, 297 : 785 - 790
  • [35] Adjuvant anthracycline-based chemotherapy for early breast cancer: do the dose and schedule matter?
    Mano, MS
    Awada, A
    Kerr, J
    Canney, P
    CANCER TREATMENT REVIEWS, 2005, 31 (02) : 69 - 78
  • [36] Diastolic Dysfunction Following Anthracycline-Based Chemotherapy in Breast Cancer Patients: Incidence and Predictors
    Serrano, Jose M.
    Gonzalez, Iria
    Del Castillo, Silvia
    Muniz, Javier
    Morales, Luis J.
    Moreno, Fernando
    Jimenez, Rosa
    Cristobal, Carmen
    Graupner, Catherine
    Talavera, Pedro
    Curcio, Alejandro
    Martinez, Paula
    Guerra, Juan A.
    Alonso, Joaquin J.
    ONCOLOGIST, 2015, 20 (08) : 864 - 872
  • [37] Role of baseline echocardiography prior to initiation of anthracycline-based chemotherapy in breast cancer patients
    Mina, Alain
    Rafei, Hind
    Khalil, Maya
    Hassoun, Yasmine
    Nasser, Zeina
    Tfayli, Arafat
    BMC CANCER, 2015, 15
  • [38] Overexpression of ANLN contributed to poor prognosis of anthracycline-based chemotherapy in breast cancer patients
    Zhan Wang
    Juan Chen
    Mei-Zuo Zhong
    Juan Huang
    Yuan-Ping Hu
    De-Yun Feng
    Zhi-Jiao Zhou
    Xiao Luo
    Zhao-Qian Liu
    Wu-Zhong Jiang
    Wei-Bing Zhou
    Cancer Chemotherapy and Pharmacology, 2017, 79 : 535 - 543
  • [39] FKBP12 is a predictive biomarker for efficacy of anthracycline-based chemotherapy in breast cancer
    Mingyou Xing
    Jun Wang
    Qin Yang
    Yu Wang
    Jiansha Li
    Jing Xiong
    Sheng Zhou
    Cancer Chemotherapy and Pharmacology, 2019, 84 : 861 - 872
  • [40] Association between the genetic polymorphisms of the pharmacokinetics of anthracycline drug and myelosuppression in a patient with breast cancer with anthracycline-based chemotherapy
    Cui, Lulu
    Huang, Jia
    Zhan, Yongtao
    Qiu, Ni
    Jin, Huan
    Li, Jia
    Huang, Huiqi
    Li, Hongsheng
    LIFE SCIENCES, 2021, 276